Ocugen, Bharat Biotech's Partner, Asks US Authorities to Approve Emergency Use Authorisation for Covaxin for Children Below 18
Bharat Biotech's partner has requested the US authorities to approve emergency use authorisation of Covaxin in the states for children below the age of 18.
- Read in
- मराठी
The approval for emergency use authorisation for Covaxin, COVID-19 vaccine developed by Bharat Biotech, has been requested by it's partner firm Ocugen in the US for children below the age of 18 years.
Bharat Biotech's US partner Ocugen announced that it had asked authorities for emergency use authorization for Covid-19 vaccine Covaxin in US, for children below 18
— ANI (@ANI) November 6, 2021
Dr Raches Ella, Bharat Biotech's Clinical Lead for COVID-19 Vaccines, Tweeted the Development:
"We are pleased to announce our EUA filing to the US-FDA through our partners- Ocugen," Bharat Biotech's clinical lead for Covid-19 vaccines, Dr Raches Ella tweeted.
— ANI (@ANI) November 6, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)
(The above story first appeared on LatestLY on Nov 06, 2021 09:52 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
